Affordable Access

Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine

Journal of Immunological Methods
Publication Date
DOI: 10.1016/j.jim.2010.11.002
  • Dc
  • Anrs-Lipo-5 Vaccine
  • Hiv
  • Vaccine Development
  • Antigen-Specific T-Cells
  • Ifn-γ
  • Medicine


Abstract In the search for a therapeutic HIV-1 vaccine, we describe herein the development of a monocyte-derived dendritic cell (DC) vaccine loaded with a mixture of HIV-1-antigen lipopeptides (ANRS HIV-LIPO-5 Vaccine). LIPO-5 is comprised of five HIV-1-antigen peptides (Gag17–35, Gag253–284, Nef66–97, Nef116–145, and Pol325–355), each covalently linked to a palmitoyl-lysylamide moiety. Monocytes enriched from HIV-1-infected highly active antiretroviral therapy (HAART)-treated patients were cultured for three days with granulocyte–macrophage colony-stimulating factor and alpha-interferon. At day 2, the DCs were loaded with ANRS HIV-LIPO-5 vaccine, activated with lipopolysaccharide, harvested at day 3 and frozen. Flow cytometry analysis of thawed DC vaccines showed expression of DC differentiation markers: CD1b/c, CD14, HLA-DR, CD11c, co-stimulatory molecule CD80 and DC maturation marker CD83. DCs were capable of eliciting an HIV-1-antigen-specific response, as measured by expansion of autologous CD4+ and CD8+ T-cells. The expanded T-cells secreted gamma-IFN and interleukin (IL)-13, but not IL-10. The safety and immunogenicity of this DC vaccine are being evaluated in a Phase I/II clinical trial in chronically HIV-1-infected patients on HAART ( identifier: NCT00796770).

There are no comments yet on this publication. Be the first to share your thoughts.